Juillet 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics et GenScript ProBio sont en train de signer un contrat pour le développement et la production de vecteurs plasmidiques et viraux pour le premier pipeline de la plateforme Advanced CAR-T Platform (plateforme ACT) d'ACT Therapeutics, qui sera également chargée de produire des matières premières pour les pipelines ultérieurs d'ACT Therapeutics. Le contrat couvrira la production de plasmides et de vecteurs viraux pour le premier pipeline de la plateforme CAR-T avancée d'ACT Therapeutics.
À la suite de cet accord, GenScript ProBio a été élevé au statut de partenaire mondial capable de prendre en charge les plateformes ACT pour les thérapies ACT.
La plateforme ACT est une technologie de thérapie cellulaire et génique de nouvelle génération qui cible les antigènes du cancer en insérant des gènes conçus pour cibler ces antigènes dans les cellules immunitaires. Ces gènes sont délivrés dans les cellules immunitaires grâce à l'utilisation de vecteurs viraux. GenScript ProBio possède un développement de processus de vecteur de virus de haute qualité et une plate-forme de service à guichet unique pour la production GMP, qui sont tous deux nécessaires au développement de la thérapie cellulaire et génique.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing leucémie. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong, PDG d'ACT Therapeutics, a déclaré : « Nous avons terminé les préparatifs pour que la plateforme ACT émerge à l'échelle mondiale grâce à un partenariat stratégique avec GenScript ProBio. Nous allons accélérer le développement de traitements ciblant les cancers solides réfractaires et incurables. »
À propos de GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Dans le cadre de la mission "Innovation par la collaboration", GenScript ProBio s'engage à aider ses clients à raccourcir le délai de développement de médicaments biologiques, de la découverte à la commercialisation, en réduisant considérablement les coûts de R&D et en construisant un avenir plus sain.
